以台灣簡明版世界衛生組織生活品質問卷為基礎的過敏性鼻炎問卷之發展

Development of an Add-On Module for the WHOQOL-BREF on Patients with Allergic Rhinitis

本研究目的為發展一份含有台灣版WHOQOL-BREF的過敏性鼻炎專一性問卷。採橫斷式研究設計。首先編制問卷原始題目，再依台灣版WHOQOL-BREF發展流程的七個步驟篩選各層面新增題目，獲得問卷初稿共52題。然後對252位過敏性鼻炎患者進行問卷之效度與信度測試。在效度方面，各題目與所屬範疇間（r = .157-.715, p < .05）、各範疇間（r = .211-.535, p < .01）皆達統計上顯著相關，具有良好的內容效度。建構效度使用多元特質多重方法，在收斂效度，量表總分、生理和環境範疇與IgE抗體間（r = -.317--.380, p < .01），以及與過敏性鼻炎鼻部症狀量表間（r = -.202--.360, p < .01）；量表的體質範疇與IgE抗體間（r = .329, p < .01），以及與過敏性鼻炎鼻部症狀量表的總分與各個症狀間（r = .187-.261, p < .01）皆達統計上顯著相關。這個結果顯著的支持新問卷能夠測量過敏性鼻炎患者生活品質之專一性。同時效標關聯效度：量表總分與台灣版SF-36各個次量表都有顯著性相關（r = .256-.542, p < .01）。在信度方面，量表總分與各範疇具有良好的內部一致性（Cronbach’s α介於.73-.81）；各範疇的再測信度（r = .719-.794, p < .01）。研究結果顯著的支持新量表的效度、信度與專一性。

The purpose of this study was to develop an add-on module for the Taiwan-version WHOQOL-BREF for assessing the quality of life of people with allergic rhinitis. A cross-sectional survey design was used. In accordance with the seven steps for the development of population-specific modules of the WHOQOL, the instrument added new items on the basis of opinions of expert groups, including patients, families and physicians, to the Taiwan-version WHOQOL-BREF measure. The new questionnaire, comprising 52 items, was tested on 252 patients with allergic rhinitis. For content validity, each item was significantly correlated with the domain to which it belonged (r = .157－.715, p < .05); and each domain was significantly correlated with each other domain (r = .211－.535, p < .01). The construct validity was examined by means of the multitrait-multimethod method. The total score and the scores on the physiological and environmental subscales showed convergent validity with the score for IgE (r = -.317－-.380, p < .01) and with the total score and the scores on the subscale of the allergic rhinitis symptom questionnaire (r = -.202－-.360, p < .01). The scores on the body constitution subscale also showed convergent validity with the score for IgE (r = .329, p < .01) and with the total score and the scores on the subscale of the allergic rhinitis symptom questionnaire (r = .187－.261, p < .01). This result supports the appropriateness of this new questionnaire specifically for assessing the quality of life of people with allergic rhinitis. As regards concurrent validity, the total score was significantly correlated with the score of all subscales in the Medical Outcomes Study Short Form Taiwan-version (SF-36) (r = .256－.542, p < .01). The internal consistency reliability established by Cronbach’s alpha ranged for each domain from .73－.81. The test-retest reliability correlated for each domain of the instrument was .719－.794 (p < .01). In conclusion, the add-on module developed in this paper for the Taiwan-version WHOQOL-BREF for patients with allergic rhinitis is reliable, valid and specific.